Compound Radar

Boston Scientific Corporation (BSX) Stock Analysis

United States · Healthcare / Medical Devices

Price $44.98
Market cap $65.19B
Next earnings Oct 28, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

80
80/100 Elite Quality
  • Financial Health 65
  • Profitability 95
  • Business Quality 80
  • Balance Sheet 55
  • Cash Flow 80

Why this rating?

Health 80/100 — Elite Quality

Strongest Profitability 95/100
Softest Balance Sheet 55/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Boston Scientific Corporation (BSX) is a Medical Devices company in the Healthcare sector. Compound Radar rates Boston Scientific Corporation 80/100 (Elite Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 18.21
  • Forward P/E 13.1
  • PEG 0.66
  • EV/Revenue 3.89

Profitability

  • Revenue Growth 7.5%
  • Gross Margin 69.2%
  • Operating Margin 22.9%
  • Net Margin 17.5%
  • ROE 15.3%

Financial strength

  • Cash $539.00M
  • Debt $12.62B
  • Net Cash $-12.09B
  • Free Cash Flow $3.40B
  • Current Ratio 1.24

Similar companies

Peers in Medical Devices, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Devices →

FAQ

How Compound Radar scores and tracks Boston Scientific Corporation (BSX).

View Methodology & FAQ →